» Articles » PMID: 21058665

Nicotinic Acetylcholine Receptor Efficacy and Pharmacological Properties of 3-(substituted Phenyl)-2β-substituted Tropanes

Overview
Journal J Med Chem
Specialty Chemistry
Date 2010 Nov 10
PMID 21058665
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

There is a need for different and better aids to tobacco product use cessation. Useful smoking cessation aids, bupropion (2) and varenicline (3), share some chemical features with 3-phenyltropanes (4), which have promise in cocaine dependence therapy. Here we report studies to generate and characterize pharmacodynamic features of 3-phenyltropane analogues. These studies extend our work on the multiple molecular target model for aids to smoking cessation. We identified several new 3-phenyltropane analogues that are superior to 2 in inhibition of dopamine, norepinephrine, and sometimes serotonin reuptake. All of these ligands also act as inhibitors of nicotinic acetylcholine receptor (nAChR) function with a selectivity profile that favors, like 2, inhibition of α3β4*-nAChR. Many of these ligands also block acute effects of nicotine-induced antinociception, locomotor activity, and hypothermia. Importantly, all except one of the analogues tested have better potencies in inhibition of nicotine conditioned place preference than 2. We have identified new compounds that have utility as research tools and possible promise for treatment of nicotine dependence.

Citing Articles

From linked open data to molecular interaction: studying selectivity trends for ligands of the human serotonin and dopamine transporter.

Zdrazil B, Hellsberg E, Viereck M, Ecker G Medchemcomm. 2016; 7(9):1819-1831.

PMID: 27891211 PMC: 5100691. DOI: 10.1039/c6md00207b.


Synthesis of 2-(substituted phenyl)-3,5,5-trimethylmorpholine analogues and their effects on monoamine uptake, nicotinic acetylcholine receptor function, and behavioral effects of nicotine.

Carroll F, Muresan A, Blough B, Navarro H, Mascarella S, Eaton J J Med Chem. 2011; 54(5):1441-8.

PMID: 21319801 PMC: 3048909. DOI: 10.1021/jm1014555.

References
1.
Damaj M, Carroll F, Eaton J, Navarro H, Blough B, Mirza S . Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol. 2004; 66(3):675-82. DOI: 10.1124/mol.104.001313. View

2.
Rollema H, Coe J, Chambers L, Hurst R, Stahl S, Williams K . Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci. 2007; 28(7):316-25. DOI: 10.1016/j.tips.2007.05.003. View

3.
Tella S, Ladenheim B, Cadet J . Differential regulation of dopamine transporter after chronic self-administration of bupropion and nomifensine. J Pharmacol Exp Ther. 1997; 281(1):508-13. View

4.
Triggle D, Kwon Y, Abraham P, Rahman M, Carroll F . Synthesis of 2-(3-substituted-1,2,4-oxadiazol-5-yl)-8-methyl-8-azabicyclo [3.2.1]octanes and 2 alpha-(3-substituted-1,2,4-oxadiazol-5-yl)-8-methyl-8- azabicyclo[3.2.1]oct-2-enes as potential muscarinic agonists. Pharm Res. 1992; 9(11):1474-9. DOI: 10.1023/a:1015871131913. View

5.
Carroll F, Blough B, Abraham P, Mills A, Holleman J, Wolckenhauer S . Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009; 52(21):6768-81. DOI: 10.1021/jm901189z. View